Scholarlink

<p>To establish a prognostic stratification nomogram for non-metastatic male breast cancer to determine which patients can benefit from chemotherapy. A population-based study was conducted using data collected from the surveillance, epidemiology, and end results database. Cox proportional hazards analysis identified significant prognostic factors for survival. A prognostic stratification model was developed using R software. Propensity score matching was implemented to balance characteristics between the chemotherapy cohort and the non-chemotherapy cohort. The multivariate analyses indicated that age, race, grade, surgery, primary tumor, marital status, T stage, and N stage were independent prognostic factors for overall survival in non-metastatic metastatic MBC patients who did not receive chemotherapy (all <i>P</i> &lt; 0.05). The C-index was 0.786 (95% CI 0.662–0.870) in the training cohort and 0.763 (95% CI 0.517–0.852) in the validation cohort. The nomogram effectively discriminated between low-risk, moderate-risk, and high-risk groups concerning OS (<i>P</i> &lt; 0.0001). The current study developed the first prognostic stratification nomogram for non-metastatic MBC and identified that patients in the moderate-risk and high-risk groups are more likely to benefit from chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development, verification, and comparison of a risk stratification model to identify potential population benefiting from chemotherapy in non-metastatic male breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月7日

查看全文
  • Mingkun Zhang,
  • Qing Yao,
  • Yuan Qin,
  • Niuniu Hou,
  • Xueyuan Tang,
  • Juliang Zhang

摘要

To establish a prognostic stratification nomogram for non-metastatic male breast cancer to determine which patients can benefit from chemotherapy. A population-based study was conducted using data collected from the surveillance, epidemiology, and end results database. Cox proportional hazards analysis identified significant prognostic factors for survival. A prognostic stratification model was developed using R software. Propensity score matching was implemented to balance characteristics between the chemotherapy cohort and the non-chemotherapy cohort. The multivariate analyses indicated that age, race, grade, surgery, primary tumor, marital status, T stage, and N stage were independent prognostic factors for overall survival in non-metastatic metastatic MBC patients who did not receive chemotherapy (all P < 0.05). The C-index was 0.786 (95% CI 0.662–0.870) in the training cohort and 0.763 (95% CI 0.517–0.852) in the validation cohort. The nomogram effectively discriminated between low-risk, moderate-risk, and high-risk groups concerning OS (P < 0.0001). The current study developed the first prognostic stratification nomogram for non-metastatic MBC and identified that patients in the moderate-risk and high-risk groups are more likely to benefit from chemotherapy.